Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Blood (2024) 144 (Supplement 1): 3800.

https://doi.org/10.1182/blood-2024-210768

Published: 2024

Journal Articles

Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network

Blood (2024) 144 (Supplement 1): 4535.

https://doi.org/10.1182/blood-2024-202477

Published: 2024

Journal Articles

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study

Blood (2024) 144 (Supplement 1): 4532.

https://doi.org/10.1182/blood-2024-211476

Published: 2024

Journal Articles

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase Showing Clinical Resistance to Frontline Treatment with Second Generation Tyrosine Kinase Inhibitors. an Italian Prospective Study from the CML Campus

Blood (2023) 142 (Supplement 1): 6363.

https://doi.org/10.1182/blood-2023-188523

Published: 2023

Journal Articles

Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-141077

Published: 2020

Journal Articles

Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study

Giorgina Specchia, MD, Patrizia Pregno, Massimo Breccia, MD, Chiara Monagheddu, Fausto Castagnetti, MDPhD, Massimiliano Bonifacio, MD, Mario Tiribelli, MD, Fabio Stagno, MD PhD, Giovanni Caocci, MD, Bruno Martino, MD, Luigiana Luciano, MD, Michele Pizzuti, MD, Antonella Gozzini, MD, Anna Rita Scortechini, MD, Francesco Albano, Micaela Bergamaschi, MD, Isabella Capodanno, MD, Andrea Patriarca, MD, Carmen Fava, Giovanna Rege Cambrin, MDPhD, Federica Sorà, MD, Sara Galimberti, MD PhD, Monica Bocchia, Gianni Binotto, MD, Giovanni Reddiconto, Attilio Guarini, MD, Alessandro Maggi, Grazia Sanpaolo, MD, Maria Stella De Candia, Valentina Giai, MD PhD, Elisabetta Abruzzese, MD, Maria Cristina Miggiano, MD, Franca Falzetti, MD, Gaetano La Barba, Giuseppe Pietrantuono, Anna Guella, MD, Luciano Levato, MD, Olga Mulas, Fabio Saccona, Gianantonio Rosti, MD, Pellegrino Musto, MD, Francesco Di Raimondo, MD, Fabrizio Pane, MD, Robin Foà, MD, Michele Baccarani, MD, Giovannino Ciccone, Giuseppe Saglio, MD PhD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-139307

Published: 2020

Journal Articles

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

Blood (2019) 134 (Supplement_1): 3000.

https://doi.org/10.1182/blood-2019-126744

Published: 2019

Journal Articles

Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients

Blood (2018) 132 (Supplement 1): 2293.

https://doi.org/10.1182/blood-2018-99-110921

Published: 2018

Journal Articles

Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial

Blood (2015) 126 (23): 91.

https://doi.org/10.1182/blood.V126.23.91.91

Published: 2015

Journal Articles

Health-Related Quality Of Life In Transfusion-Dependent Patients With Myelodysplastic Syndromes Treated With Deferasirox. A Multicenter Prospective Study

Blood (2013) 122 (21): 2980.

https://doi.org/10.1182/blood.V122.21.2980.2980

Published: 2013

Journal Articles

Patient-Reported Fatigue, Functional Aspects and Quality of Life in Elderly Patients with High-Risk Myelodysplastic Syndromes. Evidence From a Large Prospective International Study.

Blood (2012) 120 (21): 3163.

https://doi.org/10.1182/blood.V120.21.3163.3163

Published: 2012

Journal Articles

Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS)

Esther Natalie Oliva, MD, Valeria Santini, MD, Gina Zini, Giuseppe A Palumbo, Antonella Poloni, MD, Agostino Cortelezzi, MD, Maria Teresa Voso, Alfredo Molteni, Grazia Sanpaolo, MD, Antonio Marino, Filippo Rodà, MD, Caterina Alati, Francesca Ronco, Francesco Di Raimondo, Pietro Leoni, MD, Giuliana Alimena, Silvia Finotto, Roberto Latagliata, MD, Francesco Nobile, MD

Blood (2012) 120 (21): 923.

https://doi.org/10.1182/blood.V120.21.923.923

Published: 2012

Journal Articles

Relapsed or Refractory Multiple Myeloma: Prospective Study with Bortezomib, Non-Pegylated Liposomal Doxorubicin and Dexamethason (PAD Regimen)

Antonietta Pia Falcone, MD, Grazia Sanpaolo, MD, Giovanni Rossi, MD, Carlo Bodenizza, MD, Angelo Michele Carella, MD, Matteo Dell' Olio, MD, Michele Mario Greco, MD, Antonio La Sala, MD, Saverio Mantuano, MD, Lorella Melillo, MD, Emanuela Merla, MD, Michele Nobile, MD, Potito R Scalzulli, M.D., Silvana Capalbo, MD, Nicola Cascavilla, MD

Blood (2012) 120 (21): 5032.

https://doi.org/10.1182/blood.V120.21.5032.5032

Published: 2012

Journal Articles

Achievement of Complete Response Is a Strong Prognostic Factor In Elderly Newly Diagnosed Myeloma: Retrospective Analysis of 1175 Patients

Blood (2010) 116 (21): 1949.

https://doi.org/10.1182/blood.V116.21.1949.1949

Published: 2010

Journal Articles

Bone Marrow Immunological Changes During Treatment with Lenalidomide In Low and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5Q)

Esther Natalie Oliva, MD, Francesco Nobile, MD, Francesca Ronco, MD, Caterina Alati, MD, Fortunato Morabito, MD, Antonella Poloni, MD, Agostino Cortelezzi, MD, Maria Antonietta Aloe Spiriti, MD, Alessandra Ricco, Antonio Volpe, MD, Enrico Balleari, MD, Grazia Sanpaolo, MD, Massimo Breccia, MD, Cristina Clissa, Giuliana Alimena, MD, Roberto Latagliata, MD

Blood (2010) 116 (21): 2927.

https://doi.org/10.1182/blood.V116.21.2927.2927

Published: 2010

Journal Articles

Investigating Preferences and Factors Associated with Involvement In Treatment Decision-Making In Newly Diagnosed Patients with High-Risk Myelodysplastic Syndromes: An International Multicenter Study

Fabio Efficace, PhD, Gianluca Gaidano, MD, Maria Teresa Voso, MD, Giovanni Caocci, MD, Massimo Breccia, MD, Anna Angela Di Tucci, MD, Reinhard Stauder, MD, Dominik L.D. Selleslag, MD, Susan Wood, PhD, Chonghua Wan, MD, Grazia Sanpaolo, MD, Monia Lunghi, MD, Lodovico Balducci, MD, Francesco Cottone, PhD, Marco Vignetti, MD, Franco Mandelli, MD

Blood (2010) 116 (21): 4953.

https://doi.org/10.1182/blood.V116.21.4953.4953

Published: 2010

Journal Articles

A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients.

Federica Cavallo, MD, Alessandra Larocca, MD, Maria Teresa Petrucci, MD, Vincenzo Federico, MD, Antonietta Pia Falcone, MD, Grazia Sanpaolo, MD, Letizia Canepa, MD, Monica Crugnola, MD, Mario Boccadoro, MD, Antonio Palumbo, MD

Blood (2009) 114 (22): 2864.

https://doi.org/10.1182/blood.V114.22.2864.2864

Published: 2009

Journal Articles

Safety and Efficacy of Laparoscopic Splenectomy in Patients with Refractory Immune Thrombocytopenic Purpura. A Long-Term Survey

Nicola Cascavilla, Matteo Scaramuzzi, Michele Nobile, Matteo Dell’Olio, Antonietta Pia Falcone, Lorella Melillo, Grazia Sanpaolo, Potito Rosario Scalzulli, Giovanni Rossi, Antonio La Sala, Carlo Bodenizza, Giovanni D’Arena, Francesco Saverio Mantuano, Michele Mario Greco, Angelo Michele Carella, Emanuela Merla, Angelo Ambrosio, Pierluigi Di Sebastiano

Blood (2008) 112 (11): 4548.

https://doi.org/10.1182/blood.V112.11.4548.4548

Published: 2008

Journal Articles

5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program

Blood (2008) 112 (11): 2680.

https://doi.org/10.1182/blood.V112.11.2680.2680

Published: 2008

Journal Articles

5-Azacytidine for the Treatment of Acute Myeloid Leukemia: A Retrospective, Multicenter Study of 55 Patients.

Blood (2008) 112 (11): 1947.

https://doi.org/10.1182/blood.V112.11.1947.1947

Published: 2008

NARROW

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Probability of Switch of TKIs Treatment According to Baseline Features in a Large Chronic Myeloid Leukemia (CML) Population: Italian CML Network

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact Project, a CML Campus Study

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase Showing Clinical Resistance to Frontline Treatment with Second Generation Tyrosine Kinase Inhibitors. an Italian Prospective Study from the CML Campus

Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study

Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study

Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients

Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial

Health-Related Quality Of Life In Transfusion-Dependent Patients With Myelodysplastic Syndromes Treated With Deferasirox. A Multicenter Prospective Study

Patient-Reported Fatigue, Functional Aspects and Quality of Life in Elderly Patients with High-Risk Myelodysplastic Syndromes. Evidence From a Large Prospective International Study.

Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS)

Relapsed or Refractory Multiple Myeloma: Prospective Study with Bortezomib, Non-Pegylated Liposomal Doxorubicin and Dexamethason (PAD Regimen)

Achievement of Complete Response Is a Strong Prognostic Factor In Elderly Newly Diagnosed Myeloma: Retrospective Analysis of 1175 Patients

Bone Marrow Immunological Changes During Treatment with Lenalidomide In Low and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5Q)

Investigating Preferences and Factors Associated with Involvement In Treatment Decision-Making In Newly Diagnosed Patients with High-Risk Myelodysplastic Syndromes: An International Multicenter Study

A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients.

Safety and Efficacy of Laparoscopic Splenectomy in Patients with Refractory Immune Thrombocytopenic Purpura. A Long-Term Survey

5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program

5-Azacytidine for the Treatment of Acute Myeloid Leukemia: A Retrospective, Multicenter Study of 55 Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only